However, glucocorticoid use has fallen out of favor in the routine management of COVID-19 according to CDC and WHO guidelines 48 49 and evidence points to glucocorticoids attenuating anti-inflammatory angiotensin 1 - 7 levels and delaying viral clearance (Fig. 3), providing a molecular basis for avoiding their universal use.